Evommune (EVMN) Shares Outstanding (Weighted Average) (2024 - 2026)

Evommune (EVMN) has 3 years of Shares Outstanding (Weighted Average) data on file, last reported at $33.7 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 2093.54% year-over-year to $33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.7 million (up 2093.54% YoY) and the FY2025 annual result came in at $6.1 million, up 306.86% from the prior year.
• Shares Outstanding (Weighted Average) grew to $33.7 million in Q1 2026 per EVMN's latest filing, from $6.1 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $33.7 million in Q1 2026 and bottomed at $1.5 million in Q3 2024.
• The 3-year median for Shares Outstanding (Weighted Average) is $1.5 million (2025), against an average of $7.6 million.
• The widest annual swing landed in 2025, when Shares Outstanding (Weighted Average) rose 2.57%; it then soared 2093.54% in 2026.
• Tracing EVMN's Shares Outstanding (Weighted Average) over 3 years: stood at $1.5 million in 2024, then surged by 306.86% to $6.1 million in 2025, then surged by 448.67% to $33.7 million in 2026.
• Per Business Quant, the three latest EVMN Shares Outstanding (Weighted Average) figures stand at $33.7 million (Q1 2026), $6.1 million (Q4 2025), and $1.5 million (Q3 2025).

Peer Comparison